Nov 20, 2026
News
JD Bioscience Establishes R&D Collaboration with Astellas to Advance Innovative Therapies.
본문
JD Bioscience Establishes R&D Collaboration with Astellas to Advance Innovative Therapies.
International collaboration aims to advance research and development about
inflammatory disease through strategic partnership
Seoul, South Korea, November 20, 2026 — JD Bioscience Inc., a South Korean biotechnology company developing innovative therapeutics for inflammatory and fibrotic diseases, today
announced a research and development collaboration with Astellas Pharma Inc. (Astellas), a
global pharmaceutical company, through an international collaborative R&D project supported by
the Korea Technology and Information Promotion Agency (TIPA) of South Korea.
The collaboration will bring together the complementary expertise and capabilities of both
companies to support the advancement of innovative therapeutic approaches for inflammatory
disease.
Through this international collaborative R&D project, the parties aim to generate scientific insights and development data that may support future partnering or licensing opportunities related to the
results of the Project, subject to the terms of the collaboration agreement.
The collaboration with Astellas represents an important step in JD Bioscience's strategy to
expand its global partnerships and advance its research programs through collaboration.
Professor Jin Hee Ahn, CEO of JD Bioscience, commented:
“We are pleased to establish this collaboration with Astellas. We believe that combining our
research capabilities with Astellas' pharmaceutical development expertise will create valuable
opportunities to advance innovative therapeutic approaches for patients.
This collaboration also represents an important milestone in our efforts to build global partnerships and translate our research into potential new treatment options. JD Bioscience is fully committed
to working closely with Astellas to make this collaboration a success.
About JD Bioscience
JD Bioscience is a South Korean biotechnology company focused on discovering and developing innovative therapeutics for inflammatory, fibrotic, metabolic, and other diseases with significant
unmet medical needs.
The company is advancing a pipeline of small-molecule drug candidates and development-stage
therapeutic platforms across multiple disease areas, including metabolic dysfunction-associated
steatohepatitis (MASH), inflammatory bowel disease (IBD), and other inflammation- and metabolism-related disorders. JD Bioscience is also expanding its oncology research through the development of novel small-molecule payloads and actively pursuing global partnerships to accelerate
the development and commercialization of its programs.
Media & Business Development Contact
JD Bioscience Inc.


